Pharma major Cipla reported a 3.73% year-on-year (YoY) increase in its net profit for the second quarter at Rs 1,351.17 crore, up from Rs 1,302.53 crore a year ago. On a sequential basis, the company reported a 4.13% rise from Rs 1,297.62 crore in the previous quarter (Q1FY26).
Revenue from the sale of products stood at Rs 7,447.42 crore, up 6.98% YoY from Rs 6,961.22 crore a year ago. Total revenue from the operations stood at Rs 7,589.44 crore. This is Cipla’s highest ever quarterly revenue. EBITDA came in at Rs 1,895 crore, showing a marginal growth of 0.5% from the same period last year. The EBITDA margin remained stable at 25%
Key Highlights from Cipla’s Q2FY26
The Pharmaceutical segment reported a revenue of Rs 7,291.43 crore, as against Rs 6,775.56 crore in the same period a year ago. New ventures registered revenue of Rs 350.68 crore, the filing said.
Total expenses in the second quarter were higher at Rs 6,004.86 crore, as compared to Rs 5,452.57 crore in the corresponding period last fiscal, the company said.
The company has been facing pricing pressure on its generic version of Bristol Myers Squibb’s cancer drug Revlimid, a key revenue driver in the US market.
The drug is set to go off patent next year, opening the door to more competitors and intensifying price competition.
Last week, rival Dr Reddy’s reported a quarterly profit that missed analysts’ estimates and a 13% drop in its North America sales.
Key announcements by Cipla- Achin Gupta to replace Umang Vohra as MD & GCEO
Cipla announced a series of key leadership changes as part of its structured succession planning.
Umang Vohra, Managing Director and Global Chief Executive Officer (MD & GCEO), has expressed his intention not to seek re-appointment upon the completion of his current term on March 31, 2026.
Achin Gupta, currently the Global Chief Operating Officer, will replace him for a five-year term, effective April 1, 2026. Gupta will also be appointed as an Additional Director of the company with effect from April 1, 2026.
Additionally, Meera Vanjari, currently serving as General Counsel (Designate), has been appointed as Cipla’s Global General Counsel and Senior Management Personnel, effective April 1, 2026. She will succeed A. S. Kumar, whose term ends on March 31, 2026.
Key announcements by Cipla in Q2- Cipla partners with Eli Lilly
During the quarter, Cipla announced a partnership with Eli Lilly to distribute and promote Yurpeak (Tirzepatide) — the generic version of Mounjaro — in India. The drug is indicated for Type 2 diabetes and chronic weight management in adults. Under this collaboration, Eli Lilly will handle manufacturing, while Cipla will focus on distribution and promotion. The pricing will remain in line with Mounjaro.
Share price of Cipla
The share price of Cipla fell nearly 4% following the announcement of management change during its Q2 results release.